Elicit: Predictive Biomarkers for IVIG Response
Predictive Biomarkers for IVIG Response
Clinical biomarkers predicting response to IVIG therapy
Predictive biomarkers for IVIG response are disease-specific: pre-treatment inflammatory markers (C-reactive protein, liver enzymes, bilirubin) predict resistance in Kawasaki disease, while post-treatment cellular immune markers (NK cells, regulatory T cells) predict response in chronic neurological autoimmune disorders.
Abstract
Clinical biomarkers predicting IVIG response differ substantially by disease condition and reflect distinct pathophysiological mechanisms. In Kawasaki disease, pre-treatment inflammatory markers consistently predicted resistance: C-reactive protein (cut-offs 7-10 mg/dL), liver transaminases (AST ≥200 IU/L, ALT ≥80 IU/L), and total bilirubin (≥0.9 mg) demonstrated significant associations with non-response in multivariate analyses. Composite prediction scores combining multiple markers achieved 76-78% sensitivity and specificity. Post-treatment inflammatory markers measured 24 hours after infusion showed superior performance, with total leucocyte count >13.1×10⁹/L achieving 91% sensitivity and 89% specificity. In contrast, autoimmune neurological disorders demonstrated no predictive value for inflammatory markers. Instead, post-treatment cellular immune biomarkers proved informative: NK cell markers (CD56bright, KLRB1, KLRK1) measured 24 hours after IVIG initiation significantly discriminated CIDP responders from non-responders (p=0.007-0.027), while regulatory T cell frequency correlated with clinical recovery in Guillain-Barré syndrome. In dermatomyositis, higher baseline cutaneous disease activity predicted better response, whereas higher pulmonary activity predicted lower response. These divergent biomarker profiles reflect condition-specific IVIG mechanisms: acute inflammation suppression in Kawasaki disease versus immune cell modulation in chronic neurological disorders. Clinical consequences of non-response varied substantially, with Kawasaki disease non-responders experiencing coronary artery abnormalities at rates of 38-71% versus 1-5% in responders.
Methods
We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 7 key aspects that mattered most to the research question.
Medical Condition:
- Extract the specific medical condition or indication for which IVIG therapy was administered (e.g., Guillain-Barré syndrome, Kawasaki disease, myasthenia gravis, primary immunodeficiency, autoimmune neurological disorders). Include disease subtype or severity classification if specified.
Biomarker Details:
- Extract all clinical biomarkers tested for predicting IVIG response.
IVIG Response Definition:
- Extract how IVIG treatment response was defined and measured, including primary response criteria similar to fever resolution, clinical improvement scores, and functional outcomes.
Biomarker Performance:
- Extract the predictive performance of each biomarker for IVIG response, including statistical associations with response, sensitivity, specificity, and correlation coefficients.
IVIG Protocol:
- Extract details of the IVIG treatment protocol used, including IVIG dose, administration schedule, and duration.
Study Population:
- Extract characteristics of the study population relevant to biomarker performance: demographics, sample size, disease severity, and setting.
Clinical Outcomes:
- Extract observed clinical outcomes in responders vs non-responders, including response rates and specific measures.
Results
Characteristics of Included Studies
Ten studies investigating clinical biomarkers for predicting IVIG response were identified, spanning multiple autoimmune and inflammatory conditions. Five studies (50%) had full text available for detailed review.
| Study | Medical Condition | Sample Size | IVIG Dose | Response Definition |
|---|---|---|---|---|
| Y. Levy et al., 1999 | Systemic lupus erythematosus | 20 | 2 g/kg monthly over 5 days | Binary; clinical improvement with decreased SLAM score |
| A. Irgens et al., 2012 | Myasthenia gravis with worsening weakness | 51 | 2 g/kg divided over 2 days | Continuous; change in QMG Score at day 14 |
| C. Charles-Schoeman et al., 2025 | Dermatomyositis | 95 | 2.0 g/kg every 4 weeks | Continuous; total improvement score (TIS) |
| J. Hwang et al., 2010 | Kawasaki disease | 229 (206 responders, 23 non-responders) | Not specified | Binary; responder vs non-responder |
| M. Maddur et al., 2017 | Guillain-Barré syndrome | 10 | 0.4 g/kg for 3-5 consecutive days | Continuous; MRC and modified Rankin scores |
| T. Sano et al., 2006 | Acute Kawasaki disease | 112 | 2 g/kg within 2 days of onset | Binary; responsive vs non-responsive |
| A. K. Mausberg et al., 2020 | Chronic inflammatory demyelinating polyneuropathy | 29 | Not specified, treatment up to 6 months | Binary; INCAT score decline ≥1 point over 6 months |
| K. Egami et al., 2006 | Kawasaki disease | 320 (279 responders, 41 resistant) | 2 g/kg within 9 days of illness | Binary; resistance vs responder groups |
| J. Abe et al., 2008 | Kawasaki disease | Not specified | High-dose (not specified) | Binary; responsive vs nonresponsive |
| M. Fukunishi et al., 2000 | Kawasaki disease | 82 (69 responsive, 13 non-responsive) | High-dose (not specified) | Binary; defervescence within 5 days |
The studies represented diverse autoimmune conditions, with Kawasaki disease being the most extensively studied (5/10 studies). Sample sizes ranged from 10 to 320 patients. Most studies used standard high-dose IVIG protocols of 2 g/kg, though administration schedules varied. Response definitions were predominantly binary (responder vs non-responder), though some studies used continuous outcome measures.
Predictive Biomarkers by Disease Category
Kawasaki Disease
Five studies examined biomarkers predicting IVIG resistance in Kawasaki disease, demonstrating substantial heterogeneity in both biomarkers identified and their measurement timing. Pre-treatment inflammatory markers emerged as consistent predictors across multiple studies.
| Study | Pre-treatment Biomarkers | Cut-off Values | Performance Metrics | Post-treatment Biomarkers |
|---|---|---|---|---|
| T. Sano et al., 2006 | CRP, total bilirubin, AST, ALT, LDH, neutrophil count | CRP ≥7.0 mg, TB ≥0.9 mg, AST ≥200 IU/L | Multivariate p-values: CRP (p=0.009), TB (p<0.001), AST (p=0.002) | Not assessed |
| K. Egami et al., 2006 | Age, illness days, platelet count, ALT, CRP | Age <6 months, <4 illness days, platelet ≤30×10¹⁰/L, CRP ≥8 mg/dL, ALT ≥80 IU/L | Prediction score sensitivity 78%, specificity 76% | Not assessed |
| M. Fukunishi et al., 2000 | CRP, total bilirubin, LDH, gamma-glutamyltranspeptidase, hemoglobin | CRP >10 mg/dL, LDH >590 IU/L, hemoglobin <10 g/dL | Multivariate p-values: CRP (p=.006), LDH (p=.035), TB (p=.046) | Not assessed |
| J. Hwang et al., 2010 | Neutrophil differential, CRP | Pre-treatment: neutrophil >51% | Not specified | Total leucocyte >13.1×10⁹/L (sens 91%, spec 89%) |
| J. Abe et al., 2008 | Polycythemia rubra vera 1, G-CSF | Not specified | Higher in nonresponders | Not assessed |
C-reactive protein emerged as the most consistently identified pre-treatment biomarker, appearing in four of five Kawasaki studies. However, optimal CRP cut-off values varied considerably across studies: ≥7.0 mg in Sano et al., ≥8 mg/dL in Egami et al., and >10 mg/dL in Fukunishi et al.. Liver enzymes (AST, ALT) and total bilirubin also demonstrated predictive value in multiple studies.
Autoimmune Neurological Disorders
Three studies examined biomarkers in distinct neurological conditions, revealing markedly different predictive approaches. In Guillain-Barré syndrome, Maddur et al. correlated regulatory T cell (Treg) frequency with clinical recovery, suggesting Treg frequency represents a potential immunological biomarker. In CIDP, Mausberg et al. identified NK cell markers measured post-IVIG initiation as predictive.
Other Autoimmune Conditions
In systemic lupus erythematosus, Levy et al. examined autoantibodies and complement levels. In dermatomyositis, Charles-Schoeman et al. identified clinical disease activity scores as predictors. These studies highlight the diversity of biomarkers across conditions and their relation to disease mechanisms.
Synthesis
The heterogeneity in predictive biomarkers reflects differences in disease pathophysiology, IVIG mechanisms of action, and optimal measurement timing. Composite prediction scores developed may aid in identifying at-risk patients for non-response to IVIG therapy. The clinical consequences of non-response varied markedly across conditions, underscoring the need for timely identification of biomarkers and tailored treatment strategies.